Polomar Health partners with ForHumanity; $750K guaranteed for exclusive marketing of inhalable drugs

Polomar Health Services, Inc.

Guaranteed payments of $750K; $200K already received, with remaining $500K due by Oct 31, 2025.
Exclusivity for inhalable sildenafil and eletriptan through March 31, 2026, extendable via revenue milestones (e.g., $1.5M by Mar 31, 2026; $3M by Jun 30, 2026; $8M for FY 2026).
Initial term 42 months (Mar 17, 2025 – Sep 16, 2028) with automatic renewals if average annual revenues meet $3M (first renewal) and $6M (second renewal).
Fulfillment by Polomar Specialty Pharmacy; IG4 handles account management; additional $50K advance due by Sep 15, 2025.
Product pricing capped at 3% annual increase during initial term; Polomar must reserve 8,000 kits of each product for ForHumanity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.